Radius Health presents real-world data showing lower hip fracture and non-vertebral fracture rates with TYMLOS for osteoporosis management compared to teriparatide.
Radius Health presents data from real-world analysis of TYMLOS (abaloparatide), its osteoporosis drug, at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases. The study, based on 43,352 women aged 50 and older, showed that TYMLOS had a lower incidence of hip fractures and non-vertebral fractures compared to another osteoporosis drug, teriparatide. This data supports TYMLOS' efficacy and safety for managing osteoporosis.
April 16, 2024
8 Articles